1683 Participants Needed

Anti-Coagulant + Anti-Platelet Therapy for Stroke Prevention

(CAPTIVA Trial)

Recruiting at 103 trial locations
SM
RC
MP
SM
NM
TG
RD
DY
Overseen ByDixon Yang
Age: 18+
Sex: Any
Travel: May Be Covered
Trial Phase: Phase 3
Sponsor: University of Florida
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop your current medications, but it does mention that you cannot take any antithrombotic medication other than aspirin, unless it's for specific conditions like DVT prevention. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug Ticagrelor (Brilinta) for stroke prevention?

Ticagrelor, when used with aspirin, has been shown to reduce the rate of death from vascular causes, heart attacks, or strokes in patients with acute coronary syndromes, although its effectiveness specifically for stroke prevention in patients with a history of stroke is limited.12345

Is the combination of anti-coagulant and anti-platelet therapy generally safe for humans?

Ticagrelor, an anti-platelet drug, has been shown to be safe in clinical trials for acute coronary syndrome, with similar safety profiles for both its generic and branded versions. However, it carries a warning for bleeding risks, which is common for drugs that prevent blood clots.12467

How is the drug combination of Clopidogrel, Rivaroxaban, and Ticagrelor unique for stroke prevention?

This drug combination is unique because it combines both antiplatelet and anticoagulant therapies, which can significantly reduce the risk of recurrent strokes compared to using aspirin alone, although it may increase the risk of bleeding. This approach targets multiple pathways involved in blood clot formation, offering a more comprehensive prevention strategy for patients with atherosclerotic diseases.89101112

Research Team

BL

Brian L. Hoh, MD, MBA

Principal Investigator

University of Florida

MI

Marc I. Chimowitz, MBChB

Principal Investigator

Medical University of South Carolina

Eligibility Criteria

Adults aged 30-80 with recent symptoms or signs of a stroke due to 70-99% blockage in a major brain artery, who can swallow pills and have certain heart or blood vessel conditions. Excluded are those with previous stent treatments for the lesion, bleeding disorders, severe liver issues, uncontrolled high blood pressure, substance abuse, certain heart conditions that could cause clots, planned major surgeries within 90 days after joining the trial, severe neurological deficits preventing independence, life expectancy under one year due to other illnesses.

Inclusion Criteria

I have been treating my diabetes with insulin for 15 years or more.
I have a narrowed artery due to plaque buildup confirmed by imaging tests.
Index infarct is attributed to 70-99% stenosis (or flow gap on MRA) of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery) documented by CTA, MRA, or catheter angiography
See 13 more

Exclusion Criteria

Pregnancy or of childbearing potential and unwilling to use contraception for the duration of this study, or currently breastfeeding
I haven't had major surgery in the last 30 days and don't plan any in the next 90 days.
I have a heart condition that could cause blood clots.
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either ticagrelor, rivaroxaban, or clopidogrel in combination with aspirin to prevent stroke and vascular death

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on ischemic stroke, intracerebral hemorrhage, or vascular death

4 weeks

Treatment Details

Interventions

  • Clopidogrel
  • Rivaroxaban
  • Ticagrelor
Trial OverviewThe study is testing if adding rivaroxaban or ticagrelor (or both) to aspirin is better than just clopidogrel plus aspirin at reducing the risk of another stroke or death from vascular causes within a year. Participants will be randomly assigned to one of these treatment combinations.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Experimental Arm: Ticagrelor and AspirinExperimental Treatment2 Interventions
Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
Group II: Experimental Arm: Rivaroxaban and AspirinExperimental Treatment2 Interventions
Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
Group III: Standard of Care Arm: Clopidogrel and AspirinActive Control2 Interventions
Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)

Clopidogrel is already approved in European Union, United States, Canada, Japan, China for the following indications:

🇪🇺
Approved in European Union as Plavix for:
  • Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
  • Acute coronary syndrome
🇺🇸
Approved in United States as Plavix for:
  • Reduction of myocardial infarction and stroke in patients with acute coronary syndrome
  • Reduction of myocardial infarction and stroke in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease
🇨🇦
Approved in Canada as Plavix for:
  • Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
  • Acute coronary syndrome
🇯🇵
Approved in Japan as Plavix for:
  • Prevention of recurrence of ischemic cerebrovascular disorder
  • Prevention of recurrence of myocardial infarction
🇨🇳
Approved in China as Plavix for:
  • Prevention of atherothrombotic events in patients with myocardial infarction, stroke, or peripheral arterial disease
  • Acute coronary syndrome

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials
1,428
Recruited
987,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+

University of Cincinnati

Collaborator

Trials
442
Recruited
639,000+

Medical University of South Carolina

Collaborator

Trials
994
Recruited
7,408,000+

Janssen Scientific Affairs, LLC

Industry Sponsor

Trials
165
Recruited
579,000+
Ricardo Attar profile image

Ricardo Attar

Janssen Scientific Affairs, LLC

Chief Executive Officer since 2008

PhD in Molecular Biology, University of Buenos Aires

Dr. Anastasia G. Daifotis profile image

Dr. Anastasia G. Daifotis

Janssen Scientific Affairs, LLC

Chief Medical Officer since 2023

MD

AstraZeneca

Industry Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Findings from Research

Ticagrelor is a new type of P2Y(12) antagonist that works differently from traditional antiplatelet medications like clopidogrel and prasugrel, providing a potentially more effective option for treating acute coronary syndromes.
Clinical trials have shown that ticagrelor, when used with aspirin, has a favorable safety profile and can overcome some limitations associated with clopidogrel, making it a valuable addition to antiplatelet therapy.
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.Wijeyeratne, YD., Joshi, R., Heptinstall, S.[2022]
Ticagrelor (Brilinta) has been approved by the FDA as an oral antiplatelet medication to be used with low-dose aspirin for reducing thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
Ticagrelor will compete with existing medications like clopidogrel (Plavix) and prasugrel (Effient), especially as clopidogrel is expected to become available as a generic option soon.
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?[2018]
Ticagrelor, a potent oral platelet inhibitor, significantly reduces the risk of death, myocardial infarction, or stroke in patients with acute coronary syndromes compared to clopidogrel, as shown in the PLATO study.
While ticagrelor does not increase the overall rate of major bleeding compared to clopidogrel, it is associated with a higher incidence of non-procedure-related bleeding, indicating a need for careful monitoring in patients.
[Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity].Lancellotti, P.[2018]

References

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. [2022]
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)? [2018]
[Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity]. [2018]
Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome. [2021]
Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. [2021]
Testing P2Y12 platelet inhibitors generics beyond bioequivalence: a parallel single-blinded randomized trial. [2022]
Ticagrelor FDA approval issues revisited. [2018]
8.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Stroke prevention: from available antiplatelet drugs to novel molecular targets. [2019]
Combining antiplatelet and anticoagulant therapies. [2022]
10.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Current opportunities for secondary prevention of atherothrombotic stroke]. [2021]
[Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence]. [2015]
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. [2018]